Abstract: This disclosure relates to treatment of T cell diseases, particularly T cell lymphomas (TCLs) including, in particular, cutaneous T cell lymphomas (CTCLs) such as Sezary Syndrome (SS) and mycosis fungoides (MF), by targeting tumor-associated glycoprotein-72 (TAG-72).

Abstract: This disclosure relates to methods for producing immune cells with enhanced function. More specifically, disclosed herein is a method for enhancing the function of an immune cell comprising modifying an immune cell to inhibit the function of at least one gene selected from the group consisting of RC3H1, RC3H2, A2AR, FAS, TGFBR1, and TGFBR2. Also disclosed herein is a method comprising modifying a stem or progenitor cell capable of differentiating into an immune cell to inhibit the function of at least one gene selected from the group consisting of RC3H1, RC3H2, A2AR, FAS, TGFBR1, and TGFBR2. Also disclosed herein are immune cells or stem cells made by the present methods, as well as the use of immune cells in therapeutic treatment.

Abstract: This disclosure relates to immune cells (such as T cells or NK cells) modified in their cell surface receptors to recognize one or more target antigens, in particular tumor-associated antigens. This disclosure also relates to a simple method for editing cell receptors, in particular cell surface receptors naturally expressed by immune cells such as T cells or NK cells, to create modified immune cells (e.g., cytotoxic cells) targeted against one or more target antigens, in particular tumor-associated antigens. Further, this disclosure relates to stem cells modified in one or more endogenous genes encoding one or more cell surface receptors and capable of differentiating into immune cells expressing modified cell surface receptors that recognize one or more target antigens. In addition, this disclosure relates to methods of making such modified stem cells.

Abstract: This disclosure relates to treatment of T cell diseases, particularly T cell lymphomas (TCLs) including, in particular, cutaneous T cell lymphomas (CTCLs) such as Sezary Syndrome (SS) and mycosis fungoides (MF), by targeting tumor-associated glycoprotein-72 (TAG-72).